Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.

Please note that the ANZCTR will be unattended from Friday 18th April until Tuesday 22nd April due to the Easter long weekend. Submissions and updates will not be processed during that time.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03316885




Registration number
NCT03316885
Ethics application status
Date submitted
18/10/2017
Date registered
20/10/2017

Titles & IDs
Public title
Post-Market Clinical Investigation of the Clareon® IOL
Scientific title
Post-Market Clinical Investigation of the Clareon® IOL
Secondary ID [1] 0 0
ILJ466-P003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cataract 0 0
Aphakia 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Clareon® IOL
Treatment: Surgery - Cataract Surgery

Experimental: Clareon IOL - Clareon® aspheric hydrophobic acrylic intraocular lens implanted with the Alcon Monarch III-D delivery system as a replacement of the human crystalline lens during cataract surgery


Treatment: Devices: Clareon® IOL
Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.

Treatment: Surgery: Cataract Surgery
Routine small incision cataract surgery with unilateral IOL implantation
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of First Implanted Eyes Achieving Best-Corrected Distance Visual Acuity (BCDVA) of 0.3 Logarithm Minimum Angle of Resolution (logMAR) or Better at 1 Year Post-Implantation
Timepoint [1] 0 0
Year 1 post-implantation from second eye surgery
Primary outcome [2] 0 0
Percentage of Second Implanted Eyes Achieving BCDVA of 0.3 logMAR or Better at 1 Year Post-Implantation
Timepoint [2] 0 0
Year 1 post-implantation from second eye surgery
Secondary outcome [1] 0 0
Percentage of First Implanted Eyes Achieving BCDVA of 0.3 logMAR or Better at 2 Years Post-Implantation
Timepoint [1] 0 0
Year 2 post-implantation from second eye surgery
Secondary outcome [2] 0 0
Percentage of Second Implanted Eyes Achieving BCDVA of 0.3 logMAR or Better at 2 Years Post-Implantation
Timepoint [2] 0 0
Year 2 post-implantation from second eye surgery
Secondary outcome [3] 0 0
Percentage of First Implanted Eyes Achieving BCDVA of 0.3 logMAR or Better at 3 Years Post-Implantation
Timepoint [3] 0 0
Year 3 post-implantation from second eye surgery
Secondary outcome [4] 0 0
Percentage of Second Implanted Eyes Achieving BCDVA of 0.3 logMAR or Better at 3 Years Post-Implantation
Timepoint [4] 0 0
Year 3 post-implantation from second eye surgery
Secondary outcome [5] 0 0
Uncorrected Distance Visual Acuity (UCDVA) at 1 Year Post-Implantation - First Implanted Eye
Timepoint [5] 0 0
Year 1 post-implantation from second eye surgery
Secondary outcome [6] 0 0
UCDVA at 1 Year Post-Implantation - Second Implanted Eye
Timepoint [6] 0 0
Year 1 post-implantation from second eye surgery
Secondary outcome [7] 0 0
UCDVA at 2 Years Post-Implantation - First Implanted Eye
Timepoint [7] 0 0
Year 2 post-implantation from second eye surgery
Secondary outcome [8] 0 0
UCDVA at 2 Years Post-Implantation - Second Implanted Eye
Timepoint [8] 0 0
Year 2 post-implantation from second eye surgery
Secondary outcome [9] 0 0
UCDVA at 3 Years Post-Implantation - First Implanted Eye
Timepoint [9] 0 0
Year 3 post-implantation from second eye surgery
Secondary outcome [10] 0 0
UCDVA at 3 Years Post-Implantation - Second Implanted Eye
Timepoint [10] 0 0
Year 3 post-implantation from second eye surgery

Eligibility
Key inclusion criteria
Key

* Diagnosed with bilateral cataracts
* Planned small incision cataract removal surgery
* Able to comprehend and willing to sign a statement of informed consent and complete all required post-implantation visits

Key
Minimum age
22 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects who may reasonably be expected to require ocular surgical treatment or refractive surgical procedures at any time during the study
* Certain eye conditions, as specified in the protocol, including but not limited to glaucoma, diabetic retinopathy, diabetic macular edema, and macular degeneration
* Pregnant or lactating, current or planned during the course of the study

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/03/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/09/2021
Sample size
Target
Accrual to date
Final
245
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Alcon Investigative Site - Footscray
Recruitment hospital [2] 0 0
Alcon Investigative Site - Mornington
Recruitment hospital [3] 0 0
Alcon Investigative Site - Sydney
Recruitment postcode(s) [1] 0 0
3011 - Footscray
Recruitment postcode(s) [2] 0 0
3931 - Mornington
Recruitment postcode(s) [3] 0 0
2067 - Sydney
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Cedex
Country [2] 0 0
France
State/province [2] 0 0
Lyon
Country [3] 0 0
France
State/province [3] 0 0
Paris
Country [4] 0 0
Germany
State/province [4] 0 0
Frankfurt
Country [5] 0 0
Germany
State/province [5] 0 0
Heidelberg
Country [6] 0 0
Italy
State/province [6] 0 0
Perugia
Country [7] 0 0
Italy
State/province [7] 0 0
Pisa
Country [8] 0 0
Netherlands
State/province [8] 0 0
Amsterdam
Country [9] 0 0
Spain
State/province [9] 0 0
Cadiz
Country [10] 0 0
Spain
State/province [10] 0 0
Alcalá De Henares
Country [11] 0 0
Spain
State/province [11] 0 0
Oviedo
Country [12] 0 0
Spain
State/province [12] 0 0
San Sebastián
Country [13] 0 0
Spain
State/province [13] 0 0
Valencia
Country [14] 0 0
United Kingdom
State/province [14] 0 0
Carshalton
Country [15] 0 0
United Kingdom
State/province [15] 0 0
Brighton
Country [16] 0 0
United Kingdom
State/province [16] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Alcon Research
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sr. Clinical Trial Lead, CDMA, Surgical
Address 0 0
Alcon Research, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT03316885